Advanced in Gallbladder Adenocarcinoma

Dr. Paul S. Ritch

Oncology | Hematology
9200 W Wisconsin Ave, Division Of Neoplastic Diseases, 
Milwaukee, WI 
Advanced in Gallbladder Adenocarcinoma
9200 W Wisconsin Ave, Division Of Neoplastic Diseases, 
Milwaukee, WI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Ritch is an Oncologist and a Hematologist in Milwaukee, Wisconsin. Dr. Ritch is rated as an Advanced provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Cholangiocarcinoma (Bile Duct Cancer), and Pancreatectomy.

His clinical research consists of co-authoring 33 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Gallbladder Adenocarcinoma.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in WI
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

9200 W Wisconsin Ave, Division Of Neoplastic Diseases, Milwaukee, WI 53226

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients
Enrollment Status: Completed
Publish Date: March 26, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug, Radiation, Other
Study Drugs: Targeted Chemotherapy before Surgery, Standard FOLFIRINOX Chemotherapy Prior to Surgery, Gemcitabine after Surgery, Targeted Chemotherapy after Surgery
Study Phase: Phase 2
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
A SU2C Catalyst ® Randomized Phase II Trial of the PD1 Inhibitor Pembrolizumab With or Without a Vitamin D Receptor Agonist Paricalcitol in Patients With Stage IV Pancreatic Cancer Who Have Been Placed in Best Possible Response
Enrollment Status: Completed
Publish Date: December 27, 2022
Intervention Type: Drug
Study Phase: Phase 2
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Randomized Study of AM0010 in Combination With FOLFOX Compared to FOLFOX Alone as Second-line Tx in Pts With Metastatic Pancreatic Cancer That Has Progressed During or Following a First-Line Gemcitabine Containing Regimen
Enrollment Status: Completed
Publish Date: October 19, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 3
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 4 Less Clinical Trials

33 Total Publications

Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cancer.
Journal: Surgery
Published: February 17, 2020
Similar Doctors
Advanced in Gallbladder Adenocarcinoma
Dr. Shahid Shekhani
Oncology | Hematology
Advanced in Gallbladder Adenocarcinoma
Dr. Shahid Shekhani
Oncology | Hematology

Mercy Health System Corporation

N2950 State Rd, Suite 67, 
Lake Geneva, WI 
 (40.3 miles away)
262-245-0535
Languages Spoken:
English, Hindi, Punjabi, Urdu
See accepted insurances

Shahid Shekhani is an Oncologist and a Hematologist in Lake Geneva, Wisconsin. Dr. Shekhani is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), Colorectal Cancer, and Lynch Syndrome.

Abhay K. Jella
Advanced in Gallbladder Adenocarcinoma
Dr. Abhay K. Jella
Hematology | Oncology
Advanced in Gallbladder Adenocarcinoma
Dr. Abhay K. Jella
Hematology | Oncology

Aurora Cancer Care

2801 W Kinnickinnic River Pkwy, Ste 980, 
Milwaukee, WI 
 (5.1 miles away)
414-384-5111
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Abhay Jella is a Hematologist and an Oncologist in Milwaukee, Wisconsin. Dr. Jella is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Familial Pancreatic Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Advanced in Gallbladder Adenocarcinoma
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology
Advanced in Gallbladder Adenocarcinoma
Dr. Ben A. George
Oncology | Hematology Oncology | Hematology

The Medical College Of Wisconsin Inc

8701 Watertown Plank Rd, Room 4041 Mfrc, 
Milwaukee, WI 
 (0.2 miles away)
414-805-3666
Languages Spoken:
English, Malayalam
See accepted insurances
Accepting New Patients
Offers Telehealth

Ben George is an Oncologist and a Hematologist Oncology provider in Milwaukee, Wisconsin. Dr. George is rated as a Distinguished provider by MediFind in the treatment of Gallbladder Adenocarcinoma. His top areas of expertise are Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Pancreatectomy, and Endoscopy. Dr. George is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ritch's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 21 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile